-
Mashup Score: 4
RiboNN encompasses more than 140 different cell types in humans and mice to provide a transcriptome-wide atlas of TE measurements.
Source: www.insideprecisionmedicine.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 3
Microbiome-derived cell-free RNA (cfRNA) is a superior marker of early colorectal cancer (CRC) than cfRNA or cell-free DNA (cfDNA) levels.
Source: www.insideprecisionmedicine.comCategories: General Medicine News, Future of MedicineTweet-
Stage 0: Microbiome cfRNA modifications boosts colorectal cancer detection #NBTintheNews via @Inside_PM https://t.co/HAWp6VC7IQ
-
-
Mashup Score: 1Practicing Medicine in the Age of AI? - 2 month(s) ago
As I was preparing for my clinic the following day, I noticed one of the patients had already undergone genetic testing through another specialty and been diagnosed with a rare genetic disorder. Given the breadth of conditions we encounter as clinical geneticists, it’s common to come across disorders we’ve never seen before. I did my […]
Source: www.insideprecisionmedicine.comCategories: General Medicine News, Partners & KOLsTweet-
Practicing Medicine in the Age of AI? | Inside Precision Medicine https://t.co/Sn110ynPYf
-
-
Mashup Score: 8HPV Linked to Rare Nasal Cancers, Offers Treatment Options - 2 month(s) ago
The study identified common mutations in these HPV-associated SNSCCs that could be treated by a combination therapies.
Source: www.insideprecisionmedicine.comCategories: General Medicine News, Future of MedicineTweet-
HPV Linked to Rare Nasal Cancers, Offers Treatment Options The study identified common mutations in these HPV-associated SNSCCs that could be treated by combination therapies @HopkinsMedicine @hopkinskimmel #HPV #nasalcancer #DNAsequencing https://t.co/z7wQyyZ2ZA
-
-
Mashup Score: 0
A U.K. study shows that structured exercise during chemotherapy increases immune cell infiltration into tumors.
Source: www.insideprecisionmedicine.comCategories: General Medicine NewsTweet-
Exercise During Chemotherapy Boosts Immune Response in Cancer Patients https://t.co/PlXrZUdxsI
-
-
Mashup Score: 6Targeting CDK12: New Mouse Models Illuminate Path to Treat Aggressive Ovarian Cancer - 2 month(s) ago
Researchers show that CDK12 loss drives aggressive tumors—and that dual CDK12/13 degradation offers a promising therapeutic strategy.
Source: www.insideprecisionmedicine.comCategories: General Medicine NewsTweet-
Targeting CDK12: New Mouse Models Illuminate Path to Treat Aggressive Ovarian Cancer https://t.co/dXXv5vSB4j
-
-
Mashup Score: 4New AI Tool Hones in on Tumor’s Vulnerabilities - 4 month(s) ago
An algorithm, PRRDetect, that more accurately points out key mutations to target in tumors could improve cancer treatment, including with immunotherapy.
Source: www.insideprecisionmedicine.comCategories: General Medicine News, Future of MedicineTweet-
New AI Tool Hones in on Tumor’s Vulnerabilities https://t.co/ILjtrmPYiL https://t.co/5vjc8GIn81
-
-
Mashup Score: 0Coronary Artery Calcium Scores Accurately Predict Risk, Could Lower Statin Prescriptions - 4 month(s) ago
Coronary artery calcium (CAC) scores offer insights into risk of developing coronary artery disease within five years.
Source: www.insideprecisionmedicine.comCategories: General Medicine News, Partners & KOLsTweet-
Coronary Artery Calcium Scores Accurately Predict Risk, Could Lower Statin Prescriptions https://t.co/XdHsxhuDyY via @Inside_PM
-
-
Mashup Score: 3
Directly measuring gene transcription activity from DNA reveals that hyper-elevated RNA Polymerase II levels are associated with tumor aggressiveness.
Source: www.insideprecisionmedicine.comCategories: General Medicine News, Oncologists1Tweet-
Researchers from Fred Hutch and @MDAndersonNews have used a new technique that directly measures gene transcription activity from DNA to show that hyper-elevated levels of RNA Polymerase II are associated with tumor aggressiveness. https://t.co/twr3BEuXm9
-
-
Mashup Score: 0RNA Inhibitor Olpasiran Dramatically Lowers High-Risk Cholesterol in Cardiovascular Disease Patients - 6 month(s) ago
A Phase II trial shows that the RNA inhibitor olpasiran reduces lipoprotein(a) levels by over 95%, potentially lowering cardiovascular risk.
Source: www.insideprecisionmedicine.comCategories: General Medicine News, Partners & KOLsTweet-
Progress https://t.co/4BbZbvjn4N
-
@sanofi @ut_mbs @CenikLab @TexasScience AI tool boosts mRNA-based treatment designs by predicting protein output #NBTintheNews via @Inside_PM https://t.co/PBLymJPvnn